LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
LB Pharmaceuticals (LBRX) Stock Fair Value Rises As LB 102 Outlook Shifts
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80
Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
LB Pharmaceuticals Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
LB Pharmaceuticals to Participate in Upcoming September Investor Events
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals Appoints Joseph Miller CFO
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.